Core Viewpoint - Tianjin Pharmaceutical Industry Co., Ltd. (SH600488) faces regulatory scrutiny due to non-compliance in contract management and insufficient risk identification in R&D projects, leading to a significant decline in profits and operational challenges [1][2]. Group 1: Regulatory Issues - The company received an administrative regulatory decision from the Tianjin Securities Regulatory Bureau, mandating corrections due to non-standard contract management and inadequate risk identification in R&D projects [1]. - Five current and former executives received warning letters, indicating serious compliance issues within the company's governance structure [2]. Group 2: Financial Performance - For the first three quarters of 2025, the company reported a revenue of 2.232 billion yuan, a year-on-year decrease of 13.24%, and a net profit attributable to shareholders of 69.54 million yuan, down 62.75% [4]. - The company incurred a non-recurring loss of 66.17 million yuan, with antitrust penalties amounting to 69.19 million yuan, further straining profitability [2][4]. Group 3: Operational Challenges - The company's cash flow from operating activities was only 33.39 million yuan, a dramatic decline of 92.65% year-on-year, primarily due to extended payment cycles and increased market competition [4]. - The ongoing pressures from centralized procurement and stringent regulations necessitate a balance between compliance investments and R&D innovation, as the company faces compounded performance and compliance risks [4].